This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
The mergers and acquisitions market for the life science tool vendors covered by BioCommerce Week remained strong in 2007, with a little more than $5 billion spent on 18 deals during the year (see table below).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.